Rituximab or mycophenolate for steroid-dependent childhood kidney syndrome
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether rituximab works as well as mycophenolate in children whose nephrotic syndrome (kidney condition) comes back when steroid medicines are reduced. It aims to find the safest and most effective option during a relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 3 to 16 years old
- Your child has steroid-dependent nephrotic syndrome (SDNS) and is starting treatment during a relapse
- Your child uses a low steroid dose (at or below 0.3 mg/kg/day) and has used steroids for 6 months or more
- You can follow the study plan, including taking tablets by mouth if needed
- Your child can only join if nephrotic syndrome is not from another disease (not “secondary” nephrotic syndrome like lupus-related or hepatitis-related)
- Your child must not have certain blood count, liver, infection, or other serious medical problems at the start
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether rituximab alone can help children with new-onset idiopathic nephrotic syndrome. It compares the treatment approach in order to see if it improves kidney recovery and reduces disease activity.
This trial tests if a hormone called ACTH can help children with nephrotic syndrome who have frequent relapses or need steroids to stay in remission. It aims to find a treatment that may reduce the need for steroids and prevent relapses.
This trial tests if dupilumab can help children with nephrotic syndrome who still have relapses despite standard treatments. It aims to find a better way to control the disease and reduce steroid side effects.
This study tests an injection (SG301) that targets a protein called CD38 to help children whose nephrotic syndrome keeps coming back or depends on steroids. The goal is to see if the treatment can reduce relapses and the need for steroids.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
This trial tests whether a small non-surgical device can help keep children with steroid-sensitive nephrotic syndrome in remission. If it works, it could lower the chance of relapse (kidney flare-ups) and help maintain kidney health.
Hear when a new Nephrotic Syndrome in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.